Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel Therapy, Toripalimab, Discovered for the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma in combination with Coherus discovered Toripalimab, novel therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma.

Toripalimab, is an anti-PD-1 monoclonal antibodyhaving the ability to block PD-1interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function).

Blocking of PD-1 interactions with PD-L1 and PD-L2will help toboost the immune systemto attack and kill tumor cells.

Toripalimabin combination with chemotherapyachievedsignificant and clinical improvements in progression free survival (“PFS”) when compared with chemotherapy alone. In addition, toripalimab in combination with chemotherapyprovides as the first-line treatment of nasopharyngeal carcinoma (NPC).

Toripalimab, is the novel PD-1 blocking antibodydeveloped for nasopharyngeal carcinoma. Moreover, nasopharyngeal carcinoma is the aggressive cancer with no immuno-oncology treatment options approved in the United States.

Ongoing clinical trials of are being conducted to evaluate the safety and efficacy of toripalimab for tumortypes including cancers such as stomach, breast, kidney, nasopharynx, lung, esophagus and skin.

Toripalimab received Breakthrough Therapy Designation (BTD) by the United States Food and Drug Administration (“FDA”) for first line treatment of Nasopharyngeal Carcinoma.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024